FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
update
/
details

Aurigene Oncology Reports Promising Phase 1 Results for India’s First CAR-T Cell Therapy in Multiple Myeloma

NextEdge Admin

08 Oct 2024

1 min 58 sec

Dr. Reddy’s Laboratories,CAR-T cell therapy,multiple myeloma

Aurigene Oncology, a subsidiary of Dr. Reddy’s Laboratories, has announced promising Phase 1 results for Ribrecabtagene Autoleucel (DRL-1801), India’s first novel autologous CAR-T cell therapy for the treatment of multiple myeloma. The study, conducted with eight heavily pre-treated patients suffering from relapsed refractory multiple myeloma, yielded a 100% clinical response rate. Among these, 62.5% of patients achieved a stringent complete response, a remarkable outcome for a group with limited treatment options.

The therapy also demonstrated a favorable safety profile, with no high-grade events of cytokine release syndrome (CRS) or neurotoxicity, two common concerns with CAR-T therapies. Based on these encouraging results, the Drug Controller General of India (DCGI) has granted approval for Phase 2 trials, bringing hope for further advancements in the treatment of multiple myeloma in India.

Dr. Murali Ramachandra, CEO of Aurigene Oncology Limited, expressed optimism about the breakthrough. He stated, "The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India. This data represents a significant step forward, and we believe Ribrecabtagene Autoleucel has the potential to be transformative for Indian patients battling multiple myeloma."

This development positions India at the forefront of innovative cancer therapies.